Skip to main content

infectious disease "clonorchiasis" Treatment, Symptoms, Diagnosis and Industry Outlook


Pune, India, Nov, 2017 /MRFR Press Release/- Market Research Future has a half cooked research report on the Clonorchiasis market.

Market Highlights

The global clonorchiasis market is expected to grow at a CAGR of 5.4% during the forecast period.

Clonorchiasis is an infectious disease caused by the Chinese liver fluke Clonorchis sinensis. Clonorchiasis is dominant in Asian countries and regions, including South Korea, China, Northern Vietnam, and far-eastern Russia. China has the largest population of infected people. In the acute phase, heavier infections can cause fever, chills, epigastric pain, tender hepatomegaly, mild jaundice, and eosinophilia occur. Chronic cholangitis in heavy infections, which may progress to atrophy of liver parenchyma, portal fibrosis, and cirrhosis. Increasing prevalence of clonorchiasis, changing lifestyle, poor diet, and increasing geriatric population have driven the growth of the market. Moreover, increasing healthcare expenditure has fuelled the growth of the market. On the other hand, high cost of the treatment may slow the market growth..

Market Key Players

The key players for the global clonorchiasis market are Pfizer (U.S), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla (India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), Arsanis, Inc. (Austria), Novabiotics (U.K.), GlaxoSmithKline plc. (U.K.), and Teva Pharmaceutical Industries Ltd (Taiwan). 

Market Segmentation
The global clonorchiasis market is segmented on the basis of parasites, therapy, and end users.
On the basis of the parasites, the market is segmented into Clonorchis sinensis, Opisthorchis viverrini, Opisthorchis felineus, and others.
On the basis of the therapy, the market is segmented into diagnosis and treatment. The diagnosis is further segmented into microscopic examination, X-ray, serologic tests, and others. The treatment is sub-segmented into praziquantel, cesol, cisticid, biltricide, and others.
On the basis of end users, the market is segmented into hospital, clinics, and others.



Comments

Popular posts from this blog

U.S. Uterine Fibroid Market Latest Devices, Key Players Statistics Data, Regional Business Outlook 2022

U.S. Uterine Fibroid Market by Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), by Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2022 The  US Uterine Fibroid Market  report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report Major Key Players To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch. These are the Top Market...

Medical Billing Outsourcing Market Briefing 2020 By New Developments, Diagnosis by Key Applications

Medical Billing Outsourcing Market Research Report: Information by Component (In House & Outsourced), Service (Front End Service, Middle End Service, & Back End Service), End User (Hospitals, Physician’s Office, & Others) — Global Forecast till 2023 Global Medical Billing Outsourcing Market   In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue Major Key Players The key strategies followed by the players operating in the global Medical Billing Outsourcing Market were innovation, product development, acquisition, and expansion. R1 RCM Inc. Allscripts Cerner Corporation EClinical Works Experian Information Solutions Inc. GENERAL ELECTRIC COMPANY Genpact HCL Technologies Limited Kareo, Inc. McKesson Corporation Quest Diagnostics Incorporated The ...

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Factors,Leading Players, Clinical Reviews and Research Report

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 The  Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market  report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report Major Key Players To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch. These are the Top Marke...